Major Funding Boost for Pain Treatment Innovation
Latigo Biotherapeutics, a clinical-stage biotech company, has secured $150 million in Series B funding to accelerate the development of its non-opioid pain treatments. The funding round was led by Blue Owl Capital and saw participation from Qatar Investment Authority (QIA) alongside other prominent investors.
A Step Toward Safer Pain Management
The need for safer, non-addictive pain treatments is greater than ever. Latigo’s focus is on selective Nav1.8 inhibitors, a promising alternative to traditional opioids. These treatments could revolutionize pain management by targeting pain at its source without the risk of addiction.
“The field of pain management is long overdue for innovation beyond opioids, and we believe Latigo will be able to advance novel, non-addictive treatments that could make a real difference for patients,” said Kevin Raidy, Senior Managing Director at Blue Owl Capital.
Who’s Investing?
Several major players backed Latigo in this funding round, including:
- âś” Deep Track Capital
- âś” Access Biotechnology
- âś” Cormorant Asset Management
- âś” Sanofi Ventures
- âś” Rock Springs Capital
- âś” UPMC Enterprises
- âś” Kern Capital
Existing investors, such as Westlake Village BioPartners, Foresite Capital, 5AM Ventures, and Alexandria Venture Investments, also participated, reaffirming confidence in Latigo’s mission.
How Will they use the Funds?
Latigo plans to accelerate clinical trials for its Nav1.8 inhibitors, which are currently in development. The funding will also support expanding its broader drug pipeline, further pushing the boundaries of non-opioid pain management.
“The need for non-opioid pain treatments has never been more urgent, and this financing allows us to accelerate the development of our robust portfolio of pain medicines that have the potential to transform the treatment landscape,” said Nima Farzan, CEO of Latigo Biotherapeutics.
Who is Latigo Biotherapeutics?
Latigo Biotherapeutics is a biotech company dedicated to developing innovative, non-opioid pain treatments. Unlike traditional painkillers, Latigo’s approach targets the biological pathways of pain to provide safer, more effective solutions.
QIA’s Role in the Investment
The Qatar Investment Authority (QIA), a major investor in this funding round, is a sovereign wealth fund known for investing across diverse markets and sectors. By backing Latigo, QIA continues its mission of supporting innovative, high-impact ventures with long-term potential.
Looking Ahead
With this $150M investment, Latigo is set to push forward groundbreaking treatments that could reshape the future of pain management. As the demand for safer, non-addictive alternatives grows, Latigo’s research could offer millions of patients a better way to manage pain—without opioids.
